Latest American Association for Cancer Research Stories
A recently presented study revealed that the bisphosphonate clodronate had a low incidence of adverse events and toxicity among patients with breast cancer and may modestly reduce the incidence of distant metastases in postmenopausal women.
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer.
Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.
In a significant advance for patients with ductal carcinoma in situ, researchers have developed and prospectively validated a multigene test to identify the risk for recurrence of breast cancer.
Compared with women treated with whole-breast irradiation, women treated with brachytherapy experienced a twofold increased risk for losing their breasts.
Researchers may have discovered a series of genes that will help predict whether or not a woman with hormone receptor-positive invasive breast cancer will experience early, late or no recurrence of her disease.
Having diabetes or being obese after age 60 significantly increases the risk for developing breast cancer.
A new case-control study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, shows that women who participated in at least three screening mammograms had a 49 percent lower risk for breast cancer mortality.
- In medieval musical notation, a sign or neume denoting a shake or trill.